Gupta S, Wilson J M, Chowdhury J R
Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461.
Semin Liver Dis. 1992 Aug;12(3):321-31. doi: 10.1055/s-2008-1040401.
Following recent advances in molecular and cell biology, development of hepatocyte transplantation has been considerably invigorated. To study the fate of hepatocytes transplanted into the liver, new strategies have included the use of endogenously marked transgenic hepatocytes. Release of peripherally quantifiable marker proteins by transgenic hepatocytes has provided noninvasive ways to determine hepatocyte engraftment and prolonged survival. Further characterization of intrasplenic hepatocyte transplantation has established this to be the most suitable method for targeting hepatocytes to the liver. Advances in gene cloning, retrovirology, and gene transfer technology have provided further tools for accomplishing gene therapy. Practical strategies for ex vivo gene therapy involving hepatocytes have been developed by exploiting these new technologies. The potential value of hepatocyte transplantation in acute hepatic failure has begun to be reexamined. Therefore, hepatocyte transplantation can be predicted to provide new ammunition for continuing our assault on untreatable disorders. Resolution of outstanding issues should accelerate this process.
随着分子和细胞生物学领域的最新进展，肝细胞移植的发展得到了极大的推动。为了研究移植到肝脏中的肝细胞的命运，新的策略包括使用内源性标记的转基因肝细胞。转基因肝细胞释放外周可定量的标记蛋白提供了非侵入性方法来确定肝细胞的植入和长期存活。脾内肝细胞移植的进一步特征表明这是将肝细胞靶向肝脏的最合适方法。基因克隆、逆转录病毒学和基因转移技术的进展为实现基因治疗提供了更多工具。通过利用这些新技术，已经开发出了涉及肝细胞的体外基因治疗的实用策略。肝细胞移植在急性肝衰竭中的潜在价值已开始重新审视。因此，可以预测肝细胞移植将为我们继续攻克难治性疾病提供新的武器。解决突出问题应会加速这一进程。
